OKYO Pharma Limited

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory eye diseases and chronic pain. The company is dedicated to addressing significant unmet medical needs, particularly in neuropathic corneal pain (NCP) and dry eye disease (DED), by developing treatments that aim to alleviate pain, control inflammation, and enhance ocular residence time. OKYO Pharma maintains head offices in London, UK, and New York, USA, with its registered office located in Guernsey and its main country of operation in the United Kingdom.

OKYO Pharma's lead drug candidate is Urcosimod (formerly known as OK-101), a novel chemerin (ChemR23 or CMKLR1) receptor agonist designed as a non-steroidal anti-inflammatory and non-opioid analgesic. The company is advancing Urcosimod for the treatment of neuropathic corneal pain, dry eye disease, allergic conjunctivitis, and uveitis. Urcosimod has successfully completed Phase 2 trials for both NCP (Q2 2025) and DED (Q4 2023). OKYO Pharma is notably the first company to receive an Investigational New Drug (IND) application clearance from the FDA to clinically evaluate a drug specifically for NCP.

In recent developments, OKYO Pharma completed a successful Phase 2 trial for Urcosimod in neuropathic corneal pain and plans to initiate a 150-patient Phase 2b/3 multiple-dose study for NCP in the first half of 2026. The company secured approximately $20 million through a public offering in February 2026 to fund its ongoing clinical development. Leadership includes Robert J. Dempsey as Chief Executive Officer and Raj Patil as Chief Scientific Officer. Urcosimod has also received FDA Fast Track designation for neuropathic corneal pain, underscoring its potential as a first-in-class therapy in a market segment with considerable unmet needs.